Fund BasicsSee More
- Fund Family Amplify ETFs
- Assets Under Management 56,000,500
- Shares Outstanding, K 2,350
- 60-Month Beta 1.87
- Price/Earnings ttm 0.00
- Annual Dividend & Yield 0.10
- Most Recent Dividend 0.101
- Management Fee 0.75%
|Period||Period Low||Period High||Performance|
| || |
+4.40 (+23.63%)since 12/24/20
| || |
+10.40 (+82.47%)since 10/23/20
| || |
+9.59 (+71.46%)since 01/24/20
This cannabis ETF hits a new 52-week high. Are more gains in store for this ETF?
The Russell 2000 Index is up 5.9%, outperforming the gains of 4.8% for the S&P 400 Mid Cap Index and 1.8% for the S&P 500 Index.
Cannabis stocks and ETFs jumped following the Democratic victories in Georgia's two runoff elections that have spurred hopes for near-term decriminalization.
Investors seeking to take advantage of the merger deal between Tilray and Aphria could invest in any of the cannabis ETFs.
Small-cap stocks look poised to match the soaring large-cap U.S. indexes in 2021. Buy these top-ranked ETFs to play the trend.
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.
Given the prospect of loosening regulations and increased legalization, cannabis stocks are set to soar in 2021.
Cannabis stocks and the ETFs have surged lately on hopes of the legalization of marijuana at the federal level under Biden presidency.
Back-to-back upbeat vaccine update, stimulus hopes and a divided government have boosted Wall Street in November.
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of November with impressive returns of more than 47%.
|3rd Resistance Point||25.26|
|2nd Resistance Point||24.66|
|1st Resistance Point||23.84|
|1st Support Level||22.42|
|2nd Support Level||21.82|
|3rd Support Level||21.00|